Corvus Pharmaceuticals stock (CRVS) swings as $150M share sale follows eczema-data surge
Corvus Pharmaceuticals shares rose 0.3% to $21.48 by midday after announcing a $150 million underwritten stock offering. The move follows positive Phase 1 results for soquelitinib in eczema, with 75% of treated patients achieving EASI-75 versus 20% on placebo. The company paused its $100 million at-the-market program and plans to use proceeds for R&D and ongoing trials.